Avalon GloboCare launches first-in-human study of AVA-001 for leukemia, non-Hodgkin lymphoma
Avalon GloboCare Corp (NASDAQ:AVCO) on Monday provided an update of four clinical programs in cellular therapy, noting that AVA-001 entered into this month the first-in-human clinical study for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma.
The study of AVA-001, which is a leverage individualized CAR (Chimeric Antigen Receptor) T-cell therapy candidate for immuno-oncology, is being conducted at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China, the world’s single largest CAR-T treatment network with over 600 patients.
The significance of CAR-T cells is that they have been engineered to express a receptor (CAR) that recognizes a specific cancer surface target to attack. Unlike traditional small molecule or biologic treatments, the CAR-T therapies are specifically manufactured for each individual patient.
READ:Avalon GloboCare adds Cornell cellular therapy director to its advisory board
Avalon said the clinical trial of AVA-001 could result in a more powerful delivery mechanism designed to treat the individual patient. The company expects to recruit 20 patients for safety and efficacy studies of AVA-001.
The company also said its proprietary, transposon-based, multi-targeted CAR-T candidate, AVA-101, will enter the pre-clinical process development and validation phase during the third quarter of 2019 as scheduled.
Avalon, based in Freehold, New Jersey, said it could launch the first-in-human clinical trial of this next-generation of safer and more efficacious CAR-T candidate during first quarter of 2020.
The company has further developed a novel therapeutic candidate, AVA-201, for oral cancer. The company plans to launch the first-in-human clinical trial for AVA-201 during the fourth quarter of 2019 with the expectation to move toward a regulatory filing in the fourth quarter of 2020.
Treating diabetic foot ulcer
Lastly, Avalon said it is developing a clinical-grade, exosome-based therapeutic candidate, AVA-202, and plans to initiate international multi-centered clinical studies of vascular diseases and wound healing, including treatment of diabetic foot ulcer, during the fourth quarter of 2019.
“We are pleased to provide updates on our progress in advancing clinical studies using our cellular therapeutic platforms in CAR-T and stem cell derived exosomes,” said CEO Dr David Jin.
“We have successfully evolved into an active clinical stage company which we have the technology, partnerships and talent, all committed to delivering clinical execution and leadership in the areas of cellular immunotherapy and exosome technology.”
Avalon’s stock recently traded up 4.1% to $2.13 a share.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/223930/avalon-globocare-launches-first-in-human-study-of-ava-001-for-leukemia-non-hodgkin-lymphoma-223930.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Lion’s Mane Mushroom
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, But it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes:
Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity.
Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins.
Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system.
Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome.
Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function.
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules. Today Be 100% Satisfied Or Receive A Full Money Back Guarantee Order Yours Today By Following This Link.
| Online: | |
| Visits: | 1,608,451,224 |
| Stories: | 8,164,695 |
Whistler Blowers, Insiders
